Windlas Biotech's Q4 results show mixed performance. Revenue increased 18.71% to ₹2.03 billion, and EBITDA rose to ₹255.50 million. However, net profit slightly decreased by 4.18% to ₹162.80 million year-over-year. The company maintained a 12.60% EBITDA margin and recommended a dividend of ₹5.80 per equity share.